(PRESS RELEASE) VIENNA, 24-Sep-2020 — /EuropaWire/ — Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity … Read the full press release
Posted in Austria, European Union, France, Germany, Healthcare, Hungary, News, Pharma & Biotech, Science, United Kingdom
Tagged biotechnology, CEBINA, Central European Biotech Incubator and Accelerator, clinical testing, Clinical Trail, Diarrhoeal diseases, Enterotoxigenic E. coli, ETEC, European Vaccine Initiative, Eveliqure, Eveliqure Biotechnologies, Eveliqure Biotechnologies GmbH, Frank Malinoski, Gábor Somogyi, Healthcare, Horizon 2020, icddr b, PATH, Pharma & Biotech, science, Shigella, ShigETEC, SHIGETECVAX, Travel Diarrhea, University of Gothenburg, vaccine candidate, Wellcome Trust
CINRYZE is the first and only therapy indicated in the U.S. to help prevent angioedema attacks in pediatric patients with hereditary angioedema (HAE) as young as 6 Shire is the only drug developer to complete a pediatric study for the … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged Andreas Busch Ph.D., angioedema, biotechnology, CINRYZE, FDA, hereditary angioedema, rare diseases, Shire
New facility will add 30% capacity to Shire’s internal plasma manufacturing network once fully operational Expanded capacity supports continued strong growth of Shire’s leading immunoglobulin portfolio and further strengthens ability to deliver complex therapies for rare immune-mediated conditions DUBLIN, 25-Jun-2018 … Read the full press release
Participation in private placement as a cornerstone investor EBRD participates in US$ 51m equivalent private placement of Mabion Mabion is leading biotechnology company in Poland EBRD to invest US$ 18 million (PLN 61.4 million) LONDON, 26-Mar-2018 — /EuropaWire/ — The EBRD … Read the full press release
Posted in Banks, Chemicals, Financial, Investment, Poland, Science, Technology, United Kingdom
Tagged Biosimilar, biotechnology, EBRD, investment, Mabion S.A., multiple sclerosis, Private Placement, rituximab
Coventry, UK, 08-Jan-2018 — /EuropaWire/ — VirionHealth Ltd, a new biotechnology company developing novel therapeutics for respiratory viral infections, today announced that it has won non-dilutive funding worth up to $4.2 million from the US Defense Advanced Research Projects Agency (DARPA). … Read the full press release
Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration and Commercialization Agreements with Aphios Corporation, USA, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Aphios Corporation, biotech company, biotech development, biotech pharma companies, biotechnology, cannabinoid receptor, cannabinoids, central nervous system, CNS and neurological disorders, Cordoba, endocannabinoid system, multiple sclerosis, neurodegenerative diseases, novel class of compounds, therapeutics for multiple sclerosis, VivaCell Biotechnology, VivaCell Biotechnology España S.L.
Bayer foundation scholarships – EUR 200,000 for work and study abroad Support for ambitious study projects in the fields of science, engineering, medicine and teacher training in scientific subjects / Hermann Strenger scholarships to sponsor career-training projects abroad Leverkusen, 5-6-2013 … Read the full press release
Posted in Chemicals, Education, Financial, Germany, Non Profit, Pharma & Biotech, Science, Society
Tagged Bayer, Bayer foundation scholarships, Bayer Science & Education Foundation, Biochemistry, biology, biometrics, bioprocess engineering, biotechnology, career-training projects abroad, Carl Duisberg scholarship, chemical engineering, chemistry, engineering, Foundation, Hermann Strenger scholarships, Kurt Hansen scholarship, Leverkusen, medicine, Otto Bayer scholarship, pharmacy, physics, scholarships, science, Statistics, study projects, teacher training
We are supporting research and development into innovative drug treatments in Hungary 7-5-2013 — /europawire.eu/ — For well over 100 years, Hungarian pharmaceutical company Gedeon Richter has been working to improve their clients’ health and quality of life. It has stepped … Read the full press release
Posted in Banks, Business, European Union, Financial, Government, Healthcare, Hungary, Investment, Pharma & Biotech, Science
Tagged Anton Rop, biosimilars, biotechnology, EIB, equity investment, Gedeon Richter, guarantees, immunology, INNOVATION, loans, pharmaceutical company, R&D operation, Risk Sharing Finance Facility, treat cancer, Zsolt Szombathelyi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?